临床实验室自建LSC17干性评分检测用于急性髓系白血病患者快速风险评估
白血病干细胞与急性髓系白血病复发相关,LSC17基因表达评分可预测生存和治疗反应。本研究在CAP/CLIA认证实验室建立并验证了LSC17实验室自建检测,确定标本要求、合成对照和性能参数,并在参考队列中建立可用于临床风险分层的中位检测值。该检测在第二家独立CAP/CLIA认证实验室建立并用独立患者样本验证技术性能,使LSC17评分可用于初诊AML的 upfront 风险适应管理。
要点
- LSC17评分可预测AML生存结局和治疗反应,支持风险适应 upfront 治疗。
- LSC17实验室自建检测在CAP/CLIA认证实验室建立并验证。
- 参考队列中建立的中位检测值可用于初诊AML个体患者临床风险分层。
核心结论
- 本研究使LSC17评分可用于急性髓系白血病患者的初诊风险适应管理。
研究设计与样本
- 在CAP/CLIA认证实验室建立并广泛验证LSC17实验室自建检测,确定标本要求、合成对照和性能参数。
- 将LSC17检测值与参考急性髓系白血病患者队列的临床结局相关联,建立可用于临床风险分层的中位检测值。
- 在第二家独立CAP/CLIA认证实验室建立该检测,并用独立患者样本队列验证其技术性能。
主要发现
- LSC17实验室自建检测可在临床分子诊断实验室广泛部署。
- 参考队列中建立的中位检测值可用于初诊急性髓系白血病个体患者的临床风险分层。
- 第二家独立CAP/CLIA认证实验室的技术性能验证表明该检测可在其他机构实施。
临床怎么用
- 作者指出本研究使LSC17评分可用于急性髓系白血病患者的初诊风险适应管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Leukemia stem cells (LSCs) are linked to relapse in acute myeloid leukemia (AML). The LSC17 gene expression score robustly captures LSC stemness properties in AML and can be used to predict survival outcomes and response to therapy, enabling risk-adapted, upfront treatment approaches. The LSC17 score was developed and validated in a research setting. To enable widespread use of the LSC17 score in clinical decision making, we established a laboratory-developed test (LDT) for the LSC17 score that can be deployed broadly in clinical molecular diagnostic laboratories. We extensively validated the LSC17 LDT in a College of American Pathologists/Clinical Laboratory Improvements Act (CAP/CLIA)-certified laboratory, determining specimen requirements, a synthetic control, and performance parameters for the assay. Importantly, we correlated values from the LSC17 LDT to clinical outcome in a reference cohort of patients with AML, establishing a median assay value that can be used for clinical risk stratification of individual patients with newly diagnosed AML. The assay was established in a second independent CAP/CLIA-certified laboratory, and its technical performance was validated using an independent cohort of patient samples, demonstrating that the LSC17 LDT can be readily implemented in other settings. This study enables the clinical use of the LSC17 score for upfront risk-adapted management of patients with AML.
引用
- Ng SWK, Murphy T, King I, et al. A clinical laboratory-developed LSC17 stemness score assay for rapid risk assessment of patients with acute myeloid leukemia. Blood Adv. 2022. PMID: 34872104. doi:10.1182/bloodadvances.2021005741
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。